Citius Oncology, Inc. CTOR Payments to acquire in process research and development
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment.
The official record: Citius Oncology, Inc.’s 10-Q, filed February 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s payments to acquire in process research and development.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s payments to acquire in process research and development?
- Citius Oncology, Inc. (CTOR) reported payments to acquire in process research and development of $40M in Q4 2025.